|Bid||0.00 x 900|
|Ask||0.00 x 1300|
|Day's Range||45.90 - 50.09|
|52 Week Range||35.05 - 151.80|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 18, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||63.34|
On the call with me from CureVac are Franz-Werner Haas, the chief executive officer of CureVac; Klaus Edvardsen, our chief development officer; and Pierre Kemula, chief financial officer of CureVac. Mariola Fotin-Mleczek, our chief technology officer, will be available for the Q&A session.
06 billion as of September 30, 2021. CureVac continues to assess supplier commitments related to the withdrawal of first-generation COVID-19 vaccine candidate * CureVac will host a webcast and conference call on Friday, November 19, 2021, at 8 a.
TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / November 18, 2021 / CureVac N. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GSK, in the journal Nature .